Results 171 to 180 of about 2,915,798 (345)

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

open access: yesMolecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix   +13 more
wiley   +1 more source

Using nucleolytic toxins as restriction enzymes enables new RNA applications. [PDF]

open access: yesNucleic Acids Res
Rothweiler U   +11 more
europepmc   +1 more source

Restriction Enzymes as a Target for DNA-Based Sensing and Structural Rearrangement. [PDF]

open access: yesACS Omega, 2018
Buckhout-White S   +3 more
europepmc   +1 more source

Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA

open access: yesApplied and Environmental Microbiology, 1997
Wen Tso Liu   +3 more
semanticscholar   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

An enterococcal phage protein inhibits type IV restriction enzymes involved in antiphage defense. [PDF]

open access: yesNat Commun
Bullen NP   +8 more
europepmc   +1 more source

Determining if DNA Stained with a Cyanine Dye Can Be Digested with Restriction Enzymes. [PDF]

open access: yesJ Vis Exp, 2018
Maschmann A   +5 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy